Viking Therapeutics Inc., of San Diego, presented data from a phase I trial of VK5211, the company's lead program for muscle and bone disorders, at the 5th Fragility Fracture Network Global Congress 2016, in Rome. The results of the study showed VK5211 to be safe, well tolerated and to have a predictable pharmacokinetic profile in healthy women and men 65 and older. VK5211 is an orally available, nonsteroidal selective androgen receptor modulator designed to selectively stimulate muscle and bone formation with reduced activity in peripheral tissues such as skin and prostate. Viking said those characteristics may benefit patients recovering from hip fracture.